Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Wells Fargo analyst Derek Archila maintains Arvinas (NASDAQ:ARVN) with a Overweight and lowers the price target from $16 to ...
Barclays analyst Etzer Darout maintains Arvinas (NASDAQ:ARVN) with a Overweight and raises the price target from $15 to $16.
Arvinas (NASDAQ:ARVN) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.81) by 40...
NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creatin...
BTIG analyst Jeet Mukherjee maintains Arvinas (NASDAQ:ARVN) with a Buy and raises the price target from $10 to $14.
– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in mod...
– Data demonstrated that vepdegestrant maintained patients' quality of life for statistically significantly longer and dela...
